Skip to main content

Share story

Security

Cisco publishes security advisories (AV26-166) for critical vulnerabilities with active exploitation confirmed

Red maple leaf with numbers and other digital-related imagery laid over it. Image: Primary
Cisco published security advisories numbered AV26-166 on February 25, 2026. The advisories address critical vulnerabilities in several Cisco products including the Catalyst SD-WAN Controller and Manager in multiple versions. The advisories cover the Nexus 3600 and 9500-R Switching Platform as well as the Nexus 9000 Series Fabric Switches in multiple versions. They also address Cisco UCS Software in UCS Manager Mode for versions prior to 4.3(6e) and in Intersight Managed Mode for versions prior to 4.3(6.260003). Cisco has indicated that CVE-2026-20127 has been exploited. The Cybersecurity and Infrastructure Security Agency added CVE-2026-20127 to its Known Exploited Vulnerabilities Database on February 25, 2026. Cisco has indicated that CVE-2026-20128 and CVE-2026-20122 are being actively exploited. On April 20, 2026, the Cybersecurity and Infrastructure Security Agency added CVE-2026-20122, CVE-2026-20128, and CVE-2026-20133 to its Known Exploited Vulnerabilities Database. The Cyber Centre encourages users and administrators to review the provided web links, perform the suggested recommendations, and apply the necessary updates when available.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from cyber.gc.ca and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.